 |
|||||||
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
|
•• Professor
•• Internal Medicine
•• email:
Research Summary
Dr. Malaya Chatterjee’s current research is focused on anti-idiotype monoclonal antibody vaccine therapy for the treatment of colon cancer, malignant melanoma, breast cancer and lung cancer. Extensive studies are done in clinically relevant animal models to improve the efficacy of these vaccines. She and her colleagues have already demonstrated the generation of active immune responses in most cancer patients treated with these vaccines. Phase II/III clinical trials are currently planned with these anti-idiotype vaccines.
1. Saha, A., Chatterjee, S.K., Foon, K.A., Primus, F.J. and Bhattacharya-Chatterjee, M. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective anti-tumor immunity. Cancer Res. 63:2844-2854, 2003
2. Saha, A., Chatterjee, S.K., Mohanty, K., Foon, K.A., Bhattacharya-Chatterjee, M.: Dendritic cell based vaccines for immunotherapy of cancer. Cancer Therapy. 1:299-314, 2003.
3. Saha, A., Chatterjee, S.K., Foon, K.A., Primus, F.J., Sreedharan, S., Mohanty, K., and Bhattacharya-Chatterjee, M. Dendritic cells pulsed with ant anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice. Cancer Res. 64:4995-5003,2004.
4. Saha, A., Baral, R.N., Chaterjee, S.K., Mohanty, K, Pal, S., Foon, K.A., Primus, F.J., Krieg, A.M., Weiner, C.J., and Battacharya-Chatterjee, M.: CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice. Cancer Immunology Immunotherapy (in press, 2006).
5.Bhattacharya-Chatterjee, M., Rohatgi, N., Chatterjee, S.K., Saha, A., Shukla, R., Foon, K.A. Anti-idiotype antibody vaccines for the immunotherapy of cancer. In: Immunotherapy of Cancer (Disis, M.L. Ed). The Humana Press, N.J. (in press 2006).
